Skip to main content
Fig. 4 | BMC Gastroenterology

Fig. 4

From: Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis

Fig. 4

A A comparison of infliximab versus vedolizumab for key safety outcomes in patients with Crohn’s disease (≤ 1 year) Abbreviation: AE, adverse events; SAE, serious adverse events; IFX, infliximab; VDZ, vedolizumab. B. A comparison of infliximab versus vedolizumab for key safety outcomes in patients with ulcerative colitis (≤ 1 year). Abbreviation: AE, adverse events; SAE, serious adverse events; IFX, infliximab; VDZ, vedolizumab

Back to article page